- Psyence Group (PSYG) and The Goodleaf Company have signed a distribution agreement with This Works Products Ltd
- This is for the distribution and sale of the joint venture’s functional mushroom brand, GOODMIND, in the United Kingdom and Europe
- This Works is one of the leading skincare and well-being companies in the United Kingdom
- Psyence is a life science biotechnology company with a focus on natural psychedelics
- Psyence Group Inc. (PSYG) opened trading at C$0.12 per share
Psyence Group (PSYG) and The Goodleaf Company have signed an exclusive distribution agreement with This Works Products Ltd.
This is for the distribution and sale of the joint venture’s functional mushroom brand, GOODMIND, in the United Kingdom and Europe.
This Works is one of the leading skincare and well-being companies in the United Kingdom. As per the agreement, This Works will commence the sale of GOODMIND capsules through its website in November 2022. In Q1 2023, GOODMIND sachets will also become available for sale through This Works website and at select retail stores.
Dr. Neil Maresky, CEO of Psyence Group, commented on the news.
“We are delighted to expand the availability of the GOODMIND functional mushroom products in U.K and Europe. This aligns with our strategy to expand our functional mushroom product offering beyond South Africa. What makes it even more exciting is that GOODMIND is the first functional mushroom product available through This Works in markets that we believe have a significant potential consumer base.”
Warren Schewitz, Founder and CEO of Goodleaf, also commented on the news.
“We believe there is significant growth in the functional mushroom space. We are excited to leverage our branding and marketing expertise alongside the technical strength of Psyence, their world-class scientific team, and This Works to launch GOODMIND in what we believe are strategic markets for our products.”
The GOODMIND functional mushroom formulas harness the power of adaptogens, non-psychoactive fungi used for centuries in traditional medicine for their stress-relieving benefits.
Psyence is a life science biotechnology company with a focus on natural psychedelics.
Psyence Group Inc. (PSYG) opened trading at C$0.12 per share.